Patents Assigned to ADARx Pharmaceutical, Inc.
  • Publication number: 20250115915
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.
    Type: Application
    Filed: September 30, 2022
    Publication date: April 10, 2025
    Applicant: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer
  • Publication number: 20250073256
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.
    Type: Application
    Filed: May 24, 2024
    Publication date: March 6, 2025
    Applicant: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer
  • Publication number: 20240401045
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of angiotensinogen (AGT). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT protein in a cell or animal.
    Type: Application
    Filed: September 30, 2022
    Publication date: December 5, 2024
    Applicant: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz
  • Patent number: 12042509
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: July 23, 2024
    Assignee: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer
  • Publication number: 20240191229
    Abstract: Aspects of the disclosure provide nucleic acids for reducing expression of a target RNA. In some aspects, the disclosure provides nucleic acid modifications and base-pairing configurations useful in the design of nucleic acids for RNA interference.
    Type: Application
    Filed: April 13, 2022
    Publication date: June 13, 2024
    Applicant: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Zhiqing (Joel) Zhou
  • Publication number: 20240083934
    Abstract: Provided herein are N-acetylgalactosamine (GalNAc)-derived compounds, modified oligonucleotides, and methods of modulating protein function and treating diseases, disorders, and symptoms in a subject.
    Type: Application
    Filed: October 8, 2021
    Publication date: March 14, 2024
    Applicant: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Mehdi Michel Djamel Numa, Bo Cheng, Chase Robert Olsson, Chandramouli Chiruta, Indrasena Reddy Kummetha
  • Publication number: 20240041913
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of angiotensinogen (AGT). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT protein in a cell or animal.
    Type: Application
    Filed: March 31, 2023
    Publication date: February 8, 2024
    Applicant: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Kimberly Fultz
  • Publication number: 20240043836
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Complement Factor B (CFB). In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB mRNA in a cell or animal. In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB protein in a cell or animal.
    Type: Application
    Filed: November 23, 2022
    Publication date: February 8, 2024
    Applicant: ADARx Pharmaceuticals, Inc
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Sean Studer, Kimberly Fultz, Jean da Silva Correia
  • Publication number: 20230272391
    Abstract: Disclosed herein are compositions and methods for recruiting and using ADAR. In some aspects, compositions and methods for targeting ADAR activity to a desired region, sequence, or nucleotide are disclosed. In some aspects, compositions and methods for increasing the efficiency of directed ADAR editing are disclosed.
    Type: Application
    Filed: July 30, 2021
    Publication date: August 31, 2023
    Applicant: ADARx Pharmaceutical, Inc.
    Inventors: Zhen Li, Rui Zhu, Jean da Silva Correia, Kimberly Fultz, Sean Studer, Sam Lear
  • Publication number: 20230158059
    Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 25, 2023
    Applicant: ADARx Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Zhiqing (Joel) Zhou, Kimberly Fultz, Sean Studer